Free press releases distribution network?

Agency / Source: AnaSpec, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



AnaSpec Introduces Z-Fish™ Anti-p53 Antibodies - AnaSpec has announced the release of a zebrafish specific p53 antibody, the Z-Fish™ Anti-p53
AnaSpec Introduces Z-Fish™ Anti-p53 Antibodies

 

PRZOOM - /newswire/ - Fremont, CA, United States, 2009/10/02 - AnaSpec has announced the release of a zebrafish specific p53 antibody, the Z-Fish™ Anti-p53.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

This antibody was tested in IHC using a 48-hpf zebrafish embryo tail. Fluorescence detection was done with HiLyte Fluor™ 488 labeled goat anti-rabbit IgG. Upon addition of the immunizing peptide, the signal was abrogated. Fluorescent western blot analysis using HiLyte Fluor™ 750 shows an immunoreactive band 53 kD, this band was also abrogated upon addition of the immunizing peptide.

Anti-p53, Human or Mouse Specific Antibodies

One of the most important mammalian cell cycle checkpoint proteins is the tumor suppressor protein, p53. In normal, undamaged cells, p53 is rapidly degraded. However, when cells are treated with DNA damage-inducing agents, there is a transient accumulation of p53 protein and it is activated as a transcription factor. In several types of human cancers, p53 is mutated.1,2 Human p53 protein has been shown to be phosphorylated at several N-terminal and C-terminal sites that affect site-specific DNA binding and interaction with other cellular and viral proteins in vitro.3-8 Phosphorylation at serines 6, 9, 15, 20, 33, 37 occurs after cells are exposed either to ionizing radiation or to UV light.9,10 Serines 6 and 15 were demonstrated to be among the strongest and earliest phosphorylated sites in response to DNA damage-induced posttranslational modifications.11,12 AnaSpec’s collection of p53 antibody products includes both phosphospecific and non-phosphospecific solutions. Shown below are western blots of hydroxyurea-treated Cos-7 cells expressing an increasing amount of phosphorylated serine p53’s.

References:

1. Brown, JM. et al. Cancer Res. 59, 1391(1999).
2. Albrechtsen, N. et al. Oncogene 18, 7706 (1999).
3. Wang, L. et al. J. Biol Chem. 276, 43604 (2001).
4. Xirodimas, D. et al. Oncogene 20, 4972 (2001).
5. Backlund, MG. et al. Cancer Res. 61, 6577 (2001).
6. Sakaguchi, K. et al. J. Biol. Chem. 275, 9278 (2000).
7. Banin, S. et al. Science 281, 1674 (1998).
8. Canman, CE. et al. Science 281, 1677 (1998).
9. Burns, TF. and El-Deiry, WS. J. cell Physiol. 181, 231 (1999).
10. Oren, M. et al. J. Biol. Chem 274, 36031 (1999).
11. Lakin, ND. et al Oncogene 18, 7644 (1999).
12. Higashimoto, Y. et al. J. Biol. Chem. 275, 23199 (2000).

About AnaSpec
AnaSpec (anaspec.com) is a leading provider of integrated proteomics solutions to the world’s largest biotech, pharmaceutical, and academic research institutions. With a vision for innovation through synergy, AnaSpec focuses on three core technologies: peptides, detection reagents, and antibodies.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: AnaSpec, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


AnaSpec Introduces Z-Fish™ Anti-p53 Antibodies

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Ping Yang 
510-791-9560 ping[.]anaspec.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any AnaSpec, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From AnaSpec, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

Ipsen Announces Phase 3 CELESTIAL Trial of Cabozantinib Meets Primary Endpoint of Overall Survival
First Patient Treated with Microscopic Beads Pre-loaded with A Targeted Cancer Drug and Visible on CT Scans
BTG Plc Acquires Roxwood Medical
BTG and Mirada Medical Sign Three-Year Software Development Agreement
U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  RightITnow Ltd

Visit  NAKIVO, Inc.

Visit  JobsWare.com







 
  ©2017 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today